Singapore’s S*BIO Finds Ideal Partner In CTI For Its JAK2 Inhibitor Abandoned By Onyx
This article was originally published in PharmAsia News
Executive Summary
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.